<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252589</url>
  </required_header>
  <id_info>
    <org_study_id>QoL - CML0310</org_study_id>
    <nct_id>NCT01252589</nct_id>
  </id_info>
  <brief_title>Patient Reported Outcomes in Chronic Myeloid Leukemia</brief_title>
  <official_title>Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the impact of disease and treatment related burden on health-related quality of life
      (HRQOL) in patients with solid tumours has been well studied, with several clinical trials
      that included HRQOL as an endpoint, the general understanding in patients with Chronic
      Myeloid Leukaemia (CML) is lacking in comparison.

      The literature shows that patients' perspective is unique and should always be measured with
      methodologically sound instruments that are devised for this purpose.

      The main scope of this project is develop to an international validated questionnaire for the
      purpose of HRQOL assessment; such a tool will then be used to provide important data, from
      the patients' perspective, to make more informed treatment decisions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development process will follow the international guidelines published by the EORTC
      Quality of Life Group (QLG). This process will follow three main phases.

      Phase 1 of will deal with the review of the literature, identification of an item list and
      interviews with experts in the treatment of CML and CML patients (undergoing all possible
      treatments).

      In Phase II the identified issues from Phase I will be worded and translated into possible
      items for the provisional questionnaire using existing EORTC questionnaires and the EORTC QLG
      Item Bank.

      In the Phase III the provisional CML questionnaire will be pre-tested by to a larger sample
      of CML patients (not the same patients involved in previous phases) and individual structured
      interviews will be conducted as well. These latter will identify questions that might be
      irrelevant or whether there will be additional issues not previously included.

      Overall up to 480 patients will be enrolled in this study (up to 180 in phase I and up to 300
      in phase III).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of an EORTC questionnaire to assess HRQOL of patients with CML.</measure>
    <time_frame>By the end of the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between physicians' perception of relevance of HRQOL issues with that of patients.</measure>
    <time_frame>By the end of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of an EORTC CML symptom checklist.</measure>
    <time_frame>By the end of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL in CML patients undergoing 2nd line treatment with TKIs.</measure>
    <time_frame>By the end of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decision making process for choosing between different 2nd line treatments with TKIs.</measure>
    <time_frame>By the end of the study.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">480</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Adults with CML</arm_group_label>
    <description>Adult patients (18 years of age or older) with confirmed diagnosis of CML</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HRQOL questionnaire</intervention_name>
    <arm_group_label>Adults with CML</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (18 years of age or older) with confirmed diagnosis of Philadelphia
        chromosome positive CML undergoing all possible treatments available.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18 years of age or older)

          -  Confirmed diagnosis of Philadelphia chromosome positive CML

          -  Informed consent provided

          -  Patients enrolled in investigational treatment trials are eligible

          -  Ability to speak and read language of the Questionnaire

        Exclusion Criteria:

          -  Freedom from overt cognitive impairment or major psychiatric conditions that may
             confound HRQOL evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Efficace, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIMEMA DATA CENTER, ROME, ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute Harvard University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck University Hospital</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Baghdad</name>
      <address>
        <city>Baghdad</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi, Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale &quot;Binaghi&quot;, Cagliari</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori- IRST</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Sapienza Università di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tilburg University</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Iraq</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA</description>
  </link>
  <link>
    <url>http://groups.eortc.be/qol/quality-life-group</url>
    <description>EORTC Quality of Life Group</description>
  </link>
  <reference>
    <citation>Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014 Apr;23(3):825-36. doi: 10.1007/s11136-013-0523-5. Epub 2013 Sep 13.</citation>
    <PMID>24026634</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Symptoms</keyword>
  <keyword>Patient-Reported outcomes</keyword>
  <keyword>Questionnaire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

